Geron Corporation

Geron Corporation

World Rank (Jan-05-2024)
7,962
Market Cap (Jan-05-2024)
1.135 Billion USD
World Rank (Jul-30-2023)
6,549
Market Cap (Jul-30-2023)
1.618 Billion USD
World Rank (Jan-07-2022)
15,170
Market Cap (Jan-07-2022)
0.377 Billion USD
World Rank (Jan-01-2021)
11,214
Market Cap (Jan-01-2021)
0.494 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
GERN
Market Cap (Mar-08-2026)
0.98
Employee Count
107
Employee Count as of Date
As on 2022
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
1 Million USD
Annual Operating Income in USD
-138 Million USD
Annual Net Income in USD
-141 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
190 Million USD
Total Liabilities in USD
110 Million USD
Total Equity in USD
80 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
HealthCare Products
Biotechnology
Company Website
GERON CORPORATION
Wikipedia
Wikipedia
Yahoo
Yahoo @ Nasdaq
Company Profile

Geron Corporation is a Late Stage Clinical Biopharmaceutical company focused on the development and potential commercialization of a first in class telomerase inhibitor, imetelstat, an innovative therapeutic for hematologic myeloid malignancies. The headquarters is in USA.

Facts About Company

Geron Corporation Annual Total Revenue for year ending Dec-2022 was 0.5 million USD and and Net loss for year ending Dec-2022 was -141 million USD.

Geron Corporation Annual Total Revenue for year ending Dec-2021 was 1.3 million USD and and Net loss for year ending Dec-2021 was =116 million USD.

As on 2022, Geron Corporation has 107 employees.

Founded Year
1990
IPO Year
1996
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share